ArticleJTO clinical and research reports2026
First Documented Response to Tarlatamab in a Patient With Transformed SCLC Without Actionable Gene Alteration: Case Report.
Article in JTO clinical and research reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tarlatamab, a DLL3-targeting bispecific T-cell engager, has exhibited substantial survival benefits in relapsed and refractory extensive-stage SCLC. Its efficacy in transformed SCLC, however, particularly in patients without actionable genetic alterations (AGA), remains largely unknown. Histologic transformation of lung adenocarcinoma without AGAs to SCLC is rare, carrying a poor prognosis because of limited treatment options beyond platinum-based chemotherapy. Here, we report the case of a patient initially diagnosed with stage IV lung adenocarcinoma lacking AGAs, who progressed on multiple lines of systemic therapy and subsequently developed histologic transformation to SCLC. She was treated with tarlatamab, achieving 4 months of treatment response with symptomatic relief and improved performance status. This case represents the first documented evidence of the clinical benefit of tarlatamab in transformed SCLC and highlights its therapeutic potential in this challenging setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.